Investing In Secular Trends: Adoption Of AI
Seeking Alpha · 20h ago
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
NASDAQ · 1d ago
Exact Sciences Corp: Statement of changes in beneficial ownership of securities
Press release · 6d ago
Insider Sell: Exact Sciences
Insider Sell: Exact Sciences
MT Newswires · 6d ago
If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now
NASDAQ · 6d ago
Cathie Wood Onto 'Next Thing' In AI After ARK's Nvidia Exit: What's On Her Radar?
Benzinga · 6d ago
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
NASDAQ · 05/30 10:20
Exact Sciences Corp: Report of proposed sale of securities
Press release · 05/28 14:16
Guardant Health gains as Citi upgrades citing a “cleaner” narrative
Seeking Alpha · 05/26 13:36
Exact Sciences Plans To Present 15 Abstracts At The American Society Of Clinical Oncology (ASCO) Annual Meeting 2023
Benzinga · 05/26 10:59
Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023
PR Newswire · 05/26 10:58
3 High-Flying Cathie Wood Stocks That Are Up Over 50% This Year
Motley Fool · 05/25 13:15
Illumina's Fight With the FTC Over Blood Testing Could Reshape U.S. Merger Policy
Barron's · 05/25 05:00
Exact Sciences (EXAS) Gets a Buy from Stifel Nicolaus
TipRanks · 05/25 02:05
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
NASDAQ · 05/23 14:10
Applied Materials, Lowe's added to Jeffries franchise picks list
Seeking Alpha · 05/17 15:20
PR Newswire · 05/17 11:00
3 AI Stocks That Famed Investor Cathie Wood Is Betting On
NASDAQ · 05/16 21:30
Interesting EXAS Put And Call Options For October 20th
NASDAQ · 05/15 14:44
Webull provides a variety of real-time EXAS stock news. You can receive the latest news about Exact Sciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EXAS
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.